Advertisement

Pharmacy World and Science

, Volume 21, Issue 4, pp 147–151 | Cite as

Economic evaluation of pharmacy services ― fact or fiction?

  • Bethan George
  • Jonathan Silcock
Article

Abstract

Previous attempts to conduct economic evaluation of pharmacy services are almost exclusively from the US and the UK. Studies from the US concentrate largely on the drug cost savings realised by pharmacists. Few detail the costs of service provision and even fewer give an estimate of service benefits other than decreased drug expenditure. UK evaluation to date focuses on quantifying pharmacists' interventions, but there is no clear indication of the quality or the impact of these. This article proposes a model for economic evaluation and discusses the factors which make evaluation results useful to decision makers. The costs and outcomes, that need to be considered for economic evaluation, are discussed and the example of a pharmacist led anticoagulation clinic is used. The nature of modern health care systems demands that services are effective and, increasingly, cost‐effective. If pharmacy as a profession is to develop, decision makers must decide that pharmaceutical care delivered by pharmacists is a cost‐effective use of health care resources. Politics, education and cost pressures will mean that decision makers are likely to put more weight on the results of economic evaluation in future. If pharmacists do not start to provide good quality data about the costs and outcomes of pharmacy services then other evaluators will.

Economic Evaluation Decision Making Pharmacy Services 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. American Journal of Hospital Pharmacy 1990;47:533-43.PubMedGoogle Scholar
  2. 2.
    Schumock GT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services 1988-1995. Pharmacotherapy 1996;16:1188-208.PubMedGoogle Scholar
  3. 3.
    Mooney G. Economics, medicine and health care (second edition). Harvester Wheatsheaf, Hemel Hempstead, 1992.Google Scholar
  4. 4.
    Robinson R. Economic evaluation and health care. British Medical Journal 1993;307:670-3.PubMedGoogle Scholar
  5. 5.
    Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. British Journal of Clinical Pharmacology 1997;43:343-8.PubMedGoogle Scholar
  6. 6.
    Elliott R, Payne K, Silcock J. Prove the value of pharmacy. Pharmacy in Practice July/August 1997;7:349-50.Google Scholar
  7. 7.
    Kozma C.M, Reeder C.E. and Schultz R.M. Economic, clinical and humanstic outcomes: a planning model for pharmacoeconomic research. Clinical Therapeutics 1993;15:6:1121-32.Google Scholar
  8. 8.
    Robinson R. Economic evaluation and health care. British Medical Journal 1993;307:726-8.PubMedGoogle Scholar
  9. 9.
    Malek M. Glyceryl trinitrate sprays in the treatment of angina: a cost minimisation study. Pharmaceutical Journal 1996a (Nov 9);257:690-1.Google Scholar
  10. 10.
    Robinson R. Economic evaluation and health care. British Medical Journal 1993;307:793-5.PubMedGoogle Scholar
  11. 11.
    Mark DB, Haltky MA, Califf RM et al cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. NEJM 1995;332:1418-24.PubMedGoogle Scholar
  12. 12.
    Robinson R. Economic evaluation and health care. British Medical Journal 1993;307:859-62PubMedGoogle Scholar
  13. 13.
    Williams A., Economic of coronary artery bypass grafting. BMJ 1985;291:326-9PubMedGoogle Scholar
  14. 14.
    Robinson R. Economic evaluation and health care. British Medical Journal 1993;307:924-6.PubMedGoogle Scholar
  15. 15.
    Olsen, J.A. and Donaldson C., Helicopters Hearts and Hips: Using willingness to pay to set priorities for public sector health care programs Soc Sci Med. 1998 Jan; 46(1):1-12.PubMedGoogle Scholar
  16. 16.
    Munroe WP, Kunz K, Dalmady-Israel C, Potter L, Schonfield WH. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clinical Therapeutics 1997;19:113-23.PubMedGoogle Scholar
  17. 17.
    Hatoum HT. Microcost analysis of inpatient dispensing and administration of oral solids. American Journal of Hospital Pharmacy 1990;47:800-5.PubMedGoogle Scholar
  18. 18.
    Bjornson DC, Hiner WO, Potyk RP, Nelson BA et. al. Effect of pharmacists on health care outcomes in hospitalised patients. American Journal of Hospital Pharmacy 1993;50:1875-84.PubMedGoogle Scholar
  19. 19.
    Johnson JA, Bootman JL. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. American Journal of Health-Systems Pharmacy 1997;54:554-9.Google Scholar
  20. 20.
    Cousins D. Development, application and evaluation of a quality assurance instrument for clinical pharmacy services in a District General Hospital. PhD Thesis, University of Wales.Google Scholar
  21. 21.
    Hawksworth GM, Chrystyn H. Prescriber contacted interventions in a community pharmacy. Pharmaceutical Journal 1994;253:R9.Google Scholar
  22. 22.
    Dean BS, Allan EL, Barber ND, Barker KN. Comparison of medication errors in an American and a British Hospital. American Journal of Health Systems Pharmacy 1995;52:2543-9.Google Scholar
  23. 23.
    Naylor DM, Oxley D. Assessing the need for a domiciliary pharmaceutical service for elderly patients using a coding system to record and quantify data. Pharmaceutical Journal 1997, 258, 479-484.Google Scholar
  24. 24.
    Hawksworth GM, Chrystyn H. Clinical pharmacy domiciliary service: an extended role of the community pharmacist. Journal of Applied Therapeutics (in press).Google Scholar
  25. 25.
    Wright DJ, Purvis JR, Aykroyd RG, Chrystyn H. Clinical pharmacy services to residential and nursing homes: potential benefits of medication review. Pharmaceutical Journal 1994, 253, R9.Google Scholar
  26. 26.
    Corbett J. Provision of prescribing advice for nursing and residential home patients. Pharmaceutical Journal 1997;259:422-4.Google Scholar
  27. 27.
    Bond CM, Lennox AS, Sinclair HK, Silcock J, Winfield A, Stalker W. An assessment of the value of intensive pharmaceutical intervention in assisting people to stop smoking. Final report to Scottish Office Department of Health, February 1997.Google Scholar
  28. 28.
    Mays N. Health services research in pharmacy: a critical personal review. Pharmacy Practice Research Resource Centre, Manchester, 1994.Google Scholar
  29. 29.
    The evaluation of repeat dispensing. Online at http://www.york.ac.uk/depts/hsce/deptnews.htmGoogle Scholar
  30. 30.
    Anon. Pharmacists' adverse drug reaction reporting to start on April 1. Pharmaceutical Journal 1997;258:330-1.Google Scholar
  31. 31.
    Cooke J, Walley T, Drummond MF. The use of health economics by hospital pharmacist decision makers-a survey of UK chief pharmacists. Pharmaceutical Journal 1997;259:779-81.Google Scholar
  32. 32.
    Berger MC, Blomquist GC, Kenkel D, Tolley GS. Valuing changes in health risks: a comparison of alternative measures. Southern Economic Journal 1987;53:967-84.Google Scholar
  33. 33.
    George B. Cost-effectiveness league tables: their use in the decision to list a drug on the Australian Pharmaceutical Benefits Schedule. Report for the Department of Health and Family Services, Canberra, 1996.Google Scholar
  34. 34.
    George B. Harris A, Mitchell A. Reimbursement decisions and the implied value of life: cost effectiveness analysis and decisions to reimburse pharmaceuticals in Australia 1993-1996. Conference of the Australian Health Economics Society, Melbourne, 1997.Google Scholar
  35. 35.
    Elliott R, Payne K, Silcock J. Health economics: do or be done by. Pharmaceutical Journal 1996;257:832.Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Bethan George
  • Jonathan Silcock

There are no affiliations available

Personalised recommendations